Miller-Fisher syndrome associated with SARS-CoV-2: a case report

Microbes Infect. 2022 Jul-Aug;24(5):104954. doi: 10.1016/j.micinf.2022.104954. Epub 2022 Feb 28.

Abstract

SARS-CoV-2 infections are increasingly associated with neurological complications, including immune-mediated neuropathies. Miller-Fisher syndrome is a rare variant of Guillain-Barré syndrome characterised by the triad of ataxia, ophthalmoplegia and areflexia. Here we present a case of Miller-Fisher syndrome following COVID-19 infection. The clinical presentation was a short history of a rapidly-progressive peripheral sensorimotor neuropathy with bulbar dysfunction and facial weakness following mild COVID infection. Examination revealed global areflexia and a broad-based ataxic gait. CSF analysis revealed albuminocytological dissociation and neurophysiological testing later supported the diagnosis. The patient required high flow nasal oxygen therapy for respiratory dysfunction in a level 2 care setting and received immunological treatment with intravenous immunoglobulins. We conclude that Miller-Fisher syndrome needs to be considered in patients presenting with new sensorimotor dysfunction following SARS-COV-2 infection. Early recognition is key given the propensity to cause life-threatening respiratory failure, and early administration of immunological treatment is associated with improved prognosis.

Keywords: Artificial respiration; Intensive care unit; Intravenous immunoglobulins; Miller–Fisher syndrome; SARS-CoV-2.

Publication types

  • Case Reports

MeSH terms

  • COVID-19* / complications
  • Guillain-Barre Syndrome* / diagnosis
  • Guillain-Barre Syndrome* / etiology
  • Humans
  • Immunoglobulins, Intravenous / therapeutic use
  • Miller Fisher Syndrome* / complications
  • Miller Fisher Syndrome* / diagnosis
  • SARS-CoV-2

Substances

  • Immunoglobulins, Intravenous